Zydus Defeats 209-Patient Suit Over Heart Pill Marketing
By Eric Heisig (June 1, 2022, 5:27 PM EDT) — Zydus Pharmaceuticals USA Inc. shed claims by 209 people alleging they or their loved ones were harmed by the off-label marketing of a generic heart medication, with a New Jersey federal judge rejecting arguments that the company had a duty to warn prescribing physicians about the drug’s dangers.
U.S. District Judge Michael Shipp on Tuesday dismissed with prejudice the latest version of the suit against the Pennington, New Jersey-based manufacturer, reasoning that the patients and their families fell short in their failure-to-warn claims.
While they argued that Zydus did too little to dissuade doctors from prescribing the drug amiodarone for an…
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
Leave a Reply